Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by MarineJumperon Mar 23, 2020 7:50am

257 Views

Post# 30836626

Well this adds excitement

Resverlogix is prepared for immediate action to help address the global pandemic of COVID-19, to which there is no current effective treatment. We must act quickly,” said Donald McCaffrey, President and CEO of Resverlogix. “Apabetalone is the only BET inhibitor with a proven clinical safety record as shown by the results of the Phase 3 trial, BETonMACE. No other therapies in this class are prepared to directly enter late stage clinical trials and we would like to collaborate quickly with anyone who is testing drugs for COVID-19 in preclinical and clinical studies

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide